[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA26937A1 - Nouvelle composition pharmaceutique. - Google Patents

Nouvelle composition pharmaceutique.

Info

Publication number
MA26937A1
MA26937A1 MA27015A MA27015A MA26937A1 MA 26937 A1 MA26937 A1 MA 26937A1 MA 27015 A MA27015 A MA 27015A MA 27015 A MA27015 A MA 27015A MA 26937 A1 MA26937 A1 MA 26937A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
new pharmaceutical
new
composition
pharmaceutical
Prior art date
Application number
MA27015A
Other languages
English (en)
Inventor
Pierre Barbier
Paul Hadvary
Hans Lengsfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26937(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26937A1 publication Critical patent/MA26937A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
MA27015A 2000-07-28 2003-01-27 Nouvelle composition pharmaceutique. MA26937A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00116393 2000-07-28

Publications (1)

Publication Number Publication Date
MA26937A1 true MA26937A1 (fr) 2004-12-20

Family

ID=8169384

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27015A MA26937A1 (fr) 2000-07-28 2003-01-27 Nouvelle composition pharmaceutique.

Country Status (37)

Country Link
US (5) US6756364B2 (fr)
EP (1) EP1307264B1 (fr)
JP (2) JP4265911B2 (fr)
KR (1) KR100572785B1 (fr)
CN (1) CN100423715C (fr)
AR (1) AR033548A1 (fr)
AT (1) ATE279961T1 (fr)
AU (2) AU2001289699B2 (fr)
BR (1) BR0112799B1 (fr)
CA (1) CA2416901C (fr)
CZ (1) CZ302087B6 (fr)
DE (1) DE60106623T2 (fr)
EC (1) ECSP034450A (fr)
EG (1) EG24357A (fr)
ES (1) ES2230362T3 (fr)
GT (1) GT200100152A (fr)
HR (1) HRP20030029B1 (fr)
HU (1) HU229292B1 (fr)
IL (2) IL154008A0 (fr)
JO (1) JO2320B1 (fr)
MA (1) MA26937A1 (fr)
ME (1) MEP90508A (fr)
MX (1) MXPA03000771A (fr)
MY (1) MY127247A (fr)
NO (1) NO330546B1 (fr)
NZ (1) NZ523684A (fr)
PA (1) PA8523201A1 (fr)
PE (1) PE20020336A1 (fr)
PL (1) PL204443B1 (fr)
PT (1) PT1307264E (fr)
RS (1) RS50397B (fr)
RU (1) RU2241462C2 (fr)
SI (1) SI1307264T1 (fr)
TW (1) TWI275395B (fr)
UY (1) UY26860A1 (fr)
WO (1) WO2002009815A2 (fr)
ZA (1) ZA200300456B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416901C (fr) * 2000-07-28 2007-07-03 F. Hoffmann-La Roche Ag Compositions pharmaceutiques comportant un ihibiteur des lipases et un sequestrant d'acide biliaire et leurs utilisations pour la prevention et le traitement de l'obesite
AU8969601A (en) * 2000-07-28 2002-02-13 Hoffmann La Roche New use of lipase inhibitors
US7033373B2 (en) 2000-11-03 2006-04-25 Satiety, Inc. Method and device for use in minimally invasive placement of space-occupying intragastric devices
US6558400B2 (en) 2001-05-30 2003-05-06 Satiety, Inc. Obesity treatment tools and methods
US7083629B2 (en) 2001-05-30 2006-08-01 Satiety, Inc. Overtube apparatus for insertion into a body
DE60330764D1 (de) * 2002-04-26 2010-02-11 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
US6746460B2 (en) 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
US7214233B2 (en) 2002-08-30 2007-05-08 Satiety, Inc. Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
US7033384B2 (en) 2002-08-30 2006-04-25 Satiety, Inc. Stented anchoring of gastric space-occupying devices
DK1545562T3 (da) * 2002-09-09 2006-08-21 Tno Forgrenede alfa-glucaner til vægtregulering
US7220237B2 (en) 2002-10-23 2007-05-22 Satiety, Inc. Method and device for use in endoscopic organ procedures
US7229428B2 (en) 2002-10-23 2007-06-12 Satiety, Inc. Method and device for use in endoscopic organ procedures
US6656194B1 (en) 2002-11-05 2003-12-02 Satiety, Inc. Magnetic anchoring devices
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
US7175638B2 (en) 2003-04-16 2007-02-13 Satiety, Inc. Method and devices for modifying the function of a body organ
US7097650B2 (en) * 2003-10-14 2006-08-29 Satiety, Inc. System for tissue approximation and fixation
US7914543B2 (en) 2003-10-14 2011-03-29 Satiety, Inc. Single fold device for tissue fixation
US7648625B2 (en) * 2003-12-19 2010-01-19 Shell Oil Company Systems, methods, and catalysts for producing a crude product
US20050177176A1 (en) 2004-02-05 2005-08-11 Craig Gerbi Single-fold system for tissue approximation and fixation
EP1713402B1 (fr) 2004-02-13 2018-07-04 Ethicon Endo-Surgery, Inc. Dispositif pour reduction du volume stomacal
WO2006004574A2 (fr) * 2004-02-19 2006-01-12 Abbott Laboratories Methode d'utilisation de gamma cyclodextrine dans la regulation de la glycemie et de la secretion d'insuline
EP1725194B1 (fr) 2004-02-27 2018-01-17 Ethicon Endo-Surgery, Inc. Procedes et dispositifs pour reduire le volume d'organes creux
US8449560B2 (en) 2004-03-09 2013-05-28 Satiety, Inc. Devices and methods for placement of partitions within a hollow body organ
US9028511B2 (en) 2004-03-09 2015-05-12 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8252009B2 (en) 2004-03-09 2012-08-28 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8628547B2 (en) 2004-03-09 2014-01-14 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US7753870B2 (en) 2004-03-26 2010-07-13 Satiety, Inc. Systems and methods for treating obesity
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
WO2006035296A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Procede de preparation d'un derive d'orlistat utile comme standard de reference dans la determination de la purete d'orlistat et procede de preparation d'orlistat
US20060106288A1 (en) 2004-11-17 2006-05-18 Roth Alex T Remote tissue retraction device
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
RU2283114C1 (ru) * 2005-06-07 2006-09-10 Открытое акционерное общество "Нижегородский химико-фармацевтический завод" Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы
EP1897558B1 (fr) * 2005-06-09 2013-09-04 Norgine BV Preparation solide de 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
CA2610922A1 (fr) * 2005-06-13 2006-12-21 Yeda Research And Development Co. Ltd. Utilisation d'allylmercaptocaptopril pour traiter ou prevenir l'obesite et des maladies associees a l'obesite
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
CN101304739A (zh) * 2005-11-08 2008-11-12 基酶有限公司 用于治疗高磷酸盐血症的含镁聚合物
WO2007070801A2 (fr) * 2005-12-12 2007-06-21 Allaccem, Inc. Procedes et systemes de preparation de films et de revetements antimicrobiens
EP1803714A1 (fr) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Procédé de préparation de formes cristallines de orlistat
JP2009524648A (ja) * 2006-01-25 2009-07-02 イェダ リサーチ アンド デベロップメント カンパニー リミテッド アリルメルカプトカプトプリル（ｃｐｓｓａ）及び関連非対称ジスルフィドを調製するための方法
EP1818048B1 (fr) * 2006-02-14 2009-01-07 Teva Pharmaceutical Industries, Inc. Compositions pharmceutiques des polymères aminées aliphatiques et procedé pour les produire
CN101404982A (zh) * 2006-02-14 2009-04-08 特瓦制药工业有限公司 脂族胺聚合物的药物制剂和它们的制造方法
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
JP2010502590A (ja) 2006-09-01 2010-01-28 ユーエスヴィー リミテッド セベラマー塩酸塩およびその処方物の調製のためのプロセス
US20080069906A1 (en) * 2006-09-18 2008-03-20 Thompson Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
US7662373B2 (en) * 2006-09-18 2010-02-16 Thompson Ronald J Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
WO2008070308A2 (fr) * 2006-10-24 2008-06-12 Thompson Md Ronald J Procédé et composition d'une herbe carminative ou d'un complément naturel permettant de diminuer les effets néfastes de l'orlistat, un inhibiteur de lipase oral, et un procédé avec des formulations permettant simultanément de réduire un risque de fracture et d'assurer
HUE046465T2 (hu) * 2006-12-22 2020-03-30 Ironwood Pharmaceuticals Inc Epesavat megkötõ anyagokat tartalmazó készítmények nyelõcsõ-rendellenességek kezelésére
EP1944025A1 (fr) * 2007-01-09 2008-07-16 Ranbaxy Laboratories Limited Compositions pharmaceutiques stables d'orlistat
CA2683383C (fr) 2007-02-21 2016-01-05 Allaccem, Incorporated Compositions a base de composes polycycliques pontes pour l'inhibition et le traitement de maladies
ES2540551T3 (es) 2007-03-29 2015-07-10 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
PA8774201A1 (es) 2007-03-29 2009-06-23 Progenics Pharm Inc Antagonista del receptor
ES2765811T5 (es) 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
WO2009050720A1 (fr) * 2007-10-15 2009-04-23 Inventis Dds Pvt Limited Composition pharmaceutique d'orlistat
WO2009099411A1 (fr) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Préparation et utilisation de (r),(r)-2,2'-bis-méthylnaltrexone
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
KR20110059750A (ko) * 2008-09-02 2011-06-03 유에스브이 리미티드 가교 폴리머
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
US9339480B2 (en) * 2008-11-26 2016-05-17 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
EP2395987A1 (fr) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Utilisation d'une combinaison de diazoxyde et de metformine pour le traitement de l'obésité ou des troubles liés à l'obésité
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
WO2011075539A2 (fr) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Traitement de l'obésité ou du diabète avec des agents séquestrants des acides biliaires
EP3593802A3 (fr) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Inhibiteurs de recyclage d'acide biliaire et satiogènes pour le traitement du diabète, de l'obésité et des conditions gastro-intestinales inflammatoires
LT3400944T (lt) 2010-11-04 2020-09-25 Albireo Ab Ibat inhibitoriai, skirt kepenų ligų gydymui
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
KR20190135545A (ko) 2011-10-28 2019-12-06 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
WO2013063512A1 (fr) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc Inhibiteurs du recyclage de l'acide biliaire pour traitement de maladies cholestatiques hépatiques pédiatriques
EP2591768B1 (fr) * 2011-11-14 2014-07-16 Deva Holding Anonim Sirketi Formulations de dose unitaire de sevelamer et des vitamines liposolubles et des tensioactifs
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
ES2878017T3 (es) 2012-11-06 2021-11-18 Sigrid Therapeutics Ab Material de sílice poroso para uso como principio activo farmacéutico o dietético
AU2013361217B2 (en) 2012-12-21 2018-09-20 National Health Research Institutes Mesoporous silica nanoparticles for oil absorption
RU2552926C1 (ru) * 2014-06-23 2015-06-10 Общество с ограниченной ответственностью "ПРОМОМЕД" Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
CA2952406A1 (fr) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Preparation solide et procede d'inhibition ou d'attenuation de coloration de celle-ci
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
EP3012252A1 (fr) 2014-10-24 2016-04-27 Ferring BV Formes crystallines d'Elobixibat
ES2784446T3 (es) * 2016-02-09 2020-09-25 Albireo Ab Microgránulos de colestiramina y métodos para la preparación de los mismos
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP2020530448A (ja) * 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US11389545B2 (en) * 2018-01-09 2022-07-19 Aqua Regenerative Therapies Llc Bioactive nanoparticles and methods for making same
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
PE20210136A1 (es) 2018-06-20 2021-01-21 Albireo Ab Formulacion farmaceutica de odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
CN108685848B (zh) * 2018-08-13 2020-09-01 中山万汉制药有限公司 一种奥利司他口服乳剂及其制备方法
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN111297826B (zh) * 2020-04-20 2021-08-03 鲁南制药集团股份有限公司 一种稳定的奥利司他胶囊及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
CA1247547A (fr) 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
DE3414609C1 (de) * 1984-04-18 1985-06-20 Daimler-Benz Ag, 7000 Stuttgart Vorrichtung zur Beeinflussung eines Kuehlluftstromes
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5344453A (en) * 1991-05-30 1994-09-06 Boston Medical Products, Inc. Thyroplasty implant
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
CA2128044C (fr) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Compositions pharmaceutiques comportant un glucosidase et/ou un inhibiteur d'amylase, et un inhibiteur des lipases
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JP3832871B2 (ja) * 1995-04-03 2006-10-11 日本製粉株式会社 リパーゼ阻害剤
KR19980702533A (ko) 1995-12-26 1998-07-15 도리이 신이찌로 프로시아니딘을 유효성분으로 하는 항비만제
US5612026A (en) * 1996-01-25 1997-03-18 The Procter & Gamble Company Cholesterol lowering drink mix compositons
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
JP3807464B2 (ja) 1997-11-17 2006-08-09 康二 嘉島 肥満防止剤
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE69906928T2 (de) 1998-01-09 2004-02-19 Genzyme Corp., Cambridge Fettbindende polymere-lipasehemmer kombinationen zur behandlung von fettleibigkeit
FI113356B (fi) 1998-05-20 2004-04-15 Upm Kymmene Corp Pakkauksenmuodostuslaite
CA2340056C (fr) * 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Compositions pharmaceutiques comportant des inhibiteurs de lipase
BR9912979B1 (pt) * 1998-08-14 2010-09-21 composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
CA2342625A1 (fr) 1998-09-08 2000-03-16 Smithkline Beecham Corporation Comprimes a base de fibres solubles et d'un derive de lipstatine
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
WO2000043036A2 (fr) 1999-01-22 2000-07-27 Hunza Di Maria Carmela Marazzita S.A.S. Complexes de lipoproteines et compositions les contenant
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
CA2416901C (fr) * 2000-07-28 2007-07-03 F. Hoffmann-La Roche Ag Compositions pharmaceutiques comportant un ihibiteur des lipases et un sequestrant d'acide biliaire et leurs utilisations pour la prevention et le traitement de l'obesite

Also Published As

Publication number Publication date
AR033548A1 (es) 2003-12-26
KR100572785B1 (ko) 2006-04-19
EP1307264A2 (fr) 2003-05-07
ECSP034450A (es) 2003-03-10
NO330546B1 (no) 2011-05-16
SI1307264T1 (en) 2005-02-28
WO2002009815A2 (fr) 2002-02-07
US20040105838A1 (en) 2004-06-03
HRP20030029B1 (en) 2005-06-30
HRP20030029A2 (en) 2004-02-29
IL154008A0 (en) 2003-07-31
US20100203032A1 (en) 2010-08-12
EP1307264B1 (fr) 2004-10-20
US20020035089A1 (en) 2002-03-21
CA2416901A1 (fr) 2002-02-07
WO2002009815A3 (fr) 2002-04-18
EG24357A (en) 2009-03-04
CN100423715C (zh) 2008-10-08
NZ523684A (en) 2005-04-29
YU5003A (sh) 2006-01-16
PL366105A1 (en) 2005-01-24
JP4265911B2 (ja) 2009-05-20
ZA200300456B (en) 2004-04-16
DE60106623T2 (de) 2006-02-02
KR20030029796A (ko) 2003-04-16
ME00671B (fr) 2011-12-20
HU229292B1 (en) 2013-10-28
PT1307264E (pt) 2005-02-28
CZ302087B6 (cs) 2010-10-06
HUP0301281A3 (en) 2005-05-30
TWI275395B (en) 2007-03-11
US6756364B2 (en) 2004-06-29
JP2009073833A (ja) 2009-04-09
RS50397B (sr) 2009-12-31
ES2230362T3 (es) 2005-05-01
GT200100152A (es) 2002-05-16
PL204443B1 (pl) 2010-01-29
CA2416901C (fr) 2007-07-03
RU2241462C2 (ru) 2004-12-10
UY26860A1 (es) 2002-01-31
AU8969901A (en) 2002-02-13
BR0112799B1 (pt) 2017-10-24
JP2004505067A (ja) 2004-02-19
ATE279961T1 (de) 2004-11-15
HK1058636A1 (zh) 2004-05-28
BR0112799A (pt) 2003-07-01
HUP0301281A2 (hu) 2003-08-28
PA8523201A1 (es) 2002-10-24
CZ2003582A3 (cs) 2004-02-18
JO2320B1 (en) 2005-09-12
MXPA03000771A (es) 2003-06-04
NO20030418D0 (no) 2003-01-27
US20050136030A1 (en) 2005-06-23
AU2001289699B2 (en) 2006-06-01
IL154008A (en) 2011-12-29
US8071571B2 (en) 2011-12-06
DE60106623D1 (de) 2004-11-25
MEP90508A (en) 2011-12-20
NO20030418L (no) 2003-01-27
MY127247A (en) 2006-11-30
US20060269510A1 (en) 2006-11-30
PE20020336A1 (es) 2002-05-08
CN1444495A (zh) 2003-09-24

Similar Documents

Publication Publication Date Title
MA26937A1 (fr) Nouvelle composition pharmaceutique.
ITTO20000779A0 (it) Composizioni farmaceutiche.
NO20025450L (no) Ny farmasöytisk sammensetning
DK1524266T3 (da) Farmaceutisk sammensætning
FI991485L (fi) Uusi farmaseuttinen koostumus
ITTO20010005A0 (it) Formulazione farmaceutica.
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20011478L (fi) Farmaseuttinen koostumus
ITMI20010748A0 (it) Composizioni farmaceutiche
NO20015175L (no) Farmasöytisk sammensetning
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
DZ3155A1 (fr) Nouvelle composition pharmaceutique.
DK1395242T3 (da) Flydende farmaceutisk sammensætning
EE05020B1 (et) Glburiidi ravimkoostis
MXPA03001425A (es) Compuestos farmaceuticos.
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128L (fi) Farmaseuttinen koostumus
NO20031095L (no) Farmasoytiske sammensetninger
DZ3164A1 (fr) Nouvel agent pharmaceutique.
ITMI20011637A0 (it) Composizione farmaceutica contenente citalopram
FR2816953B1 (fr) Nouvelle composition collante
FI4488U1 (fi) Farmaseuttinen koostumus
DZ3163A1 (fr) Nouvelle substance pharmaceutique.
FR2779145B1 (fr) Nouvelles compositions pharmaceutiques
MA26604A1 (fr) Compositions pharmaceutiques.